Patent ID: 7507534
Filing Date: 2009-03-24
Classification: C12Q

Abstract:
1. A method for lung cancer therapy assessment comprising: (a) collecting a blood or pleural effusion sample from a human subject with lung cancer; (b) extracting total RNA of said sample; (c) amplifying a panel of gene transcripts of said total RNA by qPCR, wherein said panel of gene transcripts, named j, comprises keratin 19 (KRT19), ubiquitin thiolesterase (UCHL1), tripartite motif-containing 28 (TRIM28), and Highly similar to HSFIB1 for fibronectin; (d) measuring a qPCR threshold cycle number (C (e) calculating a differential expression ratio Q wherein (ΔC (ΔC (f) calculating a normalized expression ratio E wherein Q (g) calculating a load of cancer cells (Lc) according to (h) administering a therapy for lung cancer to said human subject with lung cancer; (i) performing steps (a) to (g) to yield a load of cancer cells (Lc) for said human subject after said therapy for lung cancer; and (j) comparing said Lc before and after administering said therapy, wherein the therapy is determined to be effective if Lc after the therapy is less than a predetermined value, or is determined to be not effective if Lc after the therapy is not less than the predetermined value.